By a News Reporter-Staff News Editor at Biotech Week -- Research findings on MRSA are discussed in a new report. According to news reporting originating from Houston, Texas, by NewsRx correspondents, research stated, "To evaluate daptomycin use for the treatment of infections with methicillin-resistant Staphylococcus aureus (MRSA) isolates having vancomycin minimum inhibitory concentrations (MICs) of 1.5 to 2 mu g/mL. The literature was retrieved through PubMed and EMBASE (January 2006 to August 2013).Study Selection and Data Extraction: English articles were reviewed."
Our news editors obtained a quote from the research from Methodist Hospital, "Studies that included separate daptomycin data (clinical outcome or in vitro surveillance) for MRSA isolates with vancomycin MICs of 1.5 to 2 mu g/mL by any testing methodology were included. Clinical and microbiological outcomes associated with daptomycin used as first-line or subsequent therapy for MRSA infections with vancomycin MICs of 1.5 to 2 mu g/mL were reported in 7 retrospective clinical studies; susceptibility information involving such isolates was reported from 12 surveillancestudies. Although not all studies demonstrated outcome differences between daptomycin and comparator treatments (usually vancomycin), when differences were reported, they were in favor of daptomycin. Individual studies found lower 60-day (8% vs 20%, P=.046) and 30-day mortality (3.5% vs 12.9%, P=.047) and increased treatment success with daptomycin (68.6% vs 43.1%, P=.008; 76.9% vs 53.8%, P=.048) in bacteremic patients. The median doses used for treatment of bacteremia were greater than that approved by the FDA for this indication (6 mg/kg/d). Current published evidence indicates daptomycin may be an acceptable alternative to vancomycin for MRSA infections, especially bacteremia, involving isolates with vancomycin MIC values of 1.5 to 2 mu g/mL."
According to the news editors, the research concluded: "Additional evidence is needed to fully elucidate daptomycin utility in this area."
For more information on this research see: Use of Daptomycin to Treat Infections With Methicillin-Resistant Staphylococcus aureus Isolates Having Vancomycin Minimum Inhibitory Concentrations of 1.5 to 2 mu g/mL. Annals of Pharmacotherapy, 2013;47(12):1654-1665. Annals of Pharmacotherapy can be contacted at: Sage Publications Inc, 2455 Teller Rd, Thousand Oaks, CA 91320, USA (see also MRSA).
The news editors report that additional information may be obtained by contacting P.M. McDaneld, Houston Methodist Hosp, Dept. of Pharm, Houston, TX 77030, United States. Additional authors for this research include L.M. Spooner, J.F. Mohr and P.P. Belliveau.
Keywords for this news article include: MRSA, Antiinfectives, Antimicrobial Resistance, Texas, Amides, Houston, Therapy, Treatment, Bacillales, Daptomycin, Vancomycin, Lipopeptides, United States, Cyclic Peptides, Drug Resistance, Organic Chemicals, Staphylococcaceae, Gram-Positive Cocci, Penicillin Resistance, Gram-Positive Bacteria, Methicillin Resistance
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC